Cover Image

HARDBACK
$52.95



View/Hide Left Panel

Table A16–1 Incidence and Mortality Rates of TB Infections

Age Groups

Population

Incidence Rates (per 100,000)

% Distribution of Cases

Cases

<1

3,963,000

2.66

0.0046

106

1–4

16,219,000

2.66

0.0189

432

5–14

38,056,000

2.66

0.0445

1,014

15–24

36,263,000

4.69

0.0746

1,700

25–34

41,670,000

9.82

0.1794

4,090

35–44

42,149,000

9.82

0.1815

4,137

45–54

30,224,000

11.63

0.1542

3,515

55–64

21,241,000

11.63

0.1084

2,470

65–74

18,964,000

15.85

0.1318

3,005

75–84

11,088,000

15.85

0.0771

1,757

85+

3,598,000

15.85

0.0250

570

Total

263,435,000

8.65

1.0000

22,795

Age Groups

Population

Mortality Rates (per 100,000)

% Distribution of Cases

Cases

<1

3,963,000

0.00

0.0000

0

1–4

16,219,000

0.02

0.0020

3

5–14

38,056,000

0.00

0.0007

1

15–24

36,263,000

0.04

0.0102

15

25–34

41,670,000

0.18

0.0495

73

35–44

42,149,000

0.33

0.0928

137

45–54

30,224,000

0.50

0.1030

152

55–64

21,241,000

0.96

0.1382

204

65–74

18,964,000

1.65

0.2121

313

75–84

11,088,000

3.22

0.2419

357

85+

3,598,000

6.14

0.1497

221

Total

263,435,000

0.56

1.0000

1,476

VACCINE DEVELOPMENT

The committee assumed that it will take 15 years until licensure of a TB vaccine and that $360 million needs to be invested. Table 4–1 summarizes vaccine development assumptions for all vaccines considered in this report.

VACCINE PROGRAM CONSIDERATIONS

Target Population

For the purposes of the calculations in this report, it is assumed that the target population for this vaccine is 500,000 high-risk people. 300,000 of those people are high-risk individuals in multi-drug-resistant areas. It was assumed that 90% of the selective high-risk population would utilize the vaccine and that



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement